Triphase Accelerator

Triphase Accelerator acquires promising cancer therapies and accelerates their development from pre-IND to clinical proof-of-concept leveraging our deep relationships with world-class scientists, clinicians and business professionals with access to state-of-the-art facilities and capabilities.

Triphase Accelerator was spun out of the Ontario Institute for Cancer Research (OICR), with support from the Fight Against Cancer Innovation Trust (FACIT), MaRS Innovation and MaRS. It has a strategic relationship with Celgene for marizomib.